Adam Gault We previously covered Teladoc (NYSE:TDOC) in May 2024, discussing why we had maintained our Hold (Neutral) rating, with the management reporting underwhelming performance metrics in FQ1'24 and numerous other players throwing in the towel on their telehealth ambitions. With bullish support yet to materialize, the insider selling intensifying, and with the stock increasingly shorted, we had believed that its reversal had been highly speculative. Since then, TDOC continues to underperform, with the ...